These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30673082)

  • 1. Evaluation of Clinical Compendia Used for Medicare Part D Coverage Determinations for Off-label Prescribing in Dermatology.
    Barbieri JS; St Claire K; Mostaghimi A; Albrecht J
    JAMA Dermatol; 2019 Mar; 155(3):315-320. PubMed ID: 30673082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review: reliability of compendia methods for off-label oncology indications.
    Abernethy AP; Raman G; Balk EM; Hammond JM; Orlando LA; Wheeler JL; Lau J; McCrory DC
    Ann Intern Med; 2009 Mar; 150(5):336-43. PubMed ID: 19221366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of evidence in drug compendia supporting off-label use of typical and atypical antipsychotic medications.
    Paczynski RP; Alexander GC; Chinchilli VM; Kruszewski SP
    Int J Risk Saf Med; 2012 Jan; 24(3):137-46. PubMed ID: 22936056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transplant recipients are vulnerable to coverage denial under Medicare Part D.
    Potter LM; Maldonado AQ; Lentine KL; Schnitzler MA; Zhang Z; Hess GP; Garrity E; Kasiske BL; Axelrod DA
    Am J Transplant; 2018 Jun; 18(6):1502-1509. PubMed ID: 29446874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compendia and anticancer therapy under Medicare.
    Tillman K; Burton B; Jacques LB; Phurrough SE
    Ann Intern Med; 2009 Mar; 150(5):348-50. PubMed ID: 19221368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Market Competition and Prices of Generic Topical Dermatology Drugs.
    Li DG; Joyce C; Mostaghimi A
    JAMA Dermatol; 2018 Dec; 154(12):1441-1446. PubMed ID: 30383117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outdated Prescription Drug Labeling: How FDA-Approved Prescribing Information Lags Behind Real-World Clinical Practice.
    Shea MB; Stewart M; Van Dyke H; Ostermann L; Allen J; Sigal E
    Ther Innov Regul Sci; 2018 Nov; 52(6):771-777. PubMed ID: 29714570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reimbursement policies constrain the practice of oncology.
    Laetz T; Silberman G
    JAMA; 1991 Dec; 266(21):2996-9. PubMed ID: 1820471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in drug coverage generosity and untreated serious mental illness: transitioning from Medicaid to Medicare Part D.
    Madden JM; Adams AS; LeCates RF; Ross-Degnan D; Zhang F; Huskamp HA; Gilden DM; Soumerai SB
    JAMA Psychiatry; 2015 Feb; 72(2):179-88. PubMed ID: 25588123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Off-label dermatologic therapies. Usage, risks, and mechanisms.
    Li VW; Jaffe MP; Li WW; Haynes HA
    Arch Dermatol; 1998 Nov; 134(11):1449-54. PubMed ID: 9828883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of drug interaction conformity in commonly used drug compendia for selected at-risk dermatologic drugs.
    Chao SD; Maibach HI
    Am J Clin Dermatol; 2005; 6(2):105-11. PubMed ID: 15799682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicare Part D payments for brand and generic drugs prescribed by dermatologists.
    Powell HB; Adamson AS
    J Am Acad Dermatol; 2018 Sep; 79(3):575-577. PubMed ID: 29477736
    [No Abstract]   [Full Text] [Related]  

  • 13. Off-label drug use in human immunodeficiency virus disease.
    Brosgart CL; Mitchell T; Charlebois E; Coleman R; Mehalko S; Young J; Abrams DI
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 May; 12(1):56-62. PubMed ID: 8624761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescribing trends for biologic drugs among Ohio dermatologists.
    Iacullo J; Kunzler E; Ezaldein HH; Scott JF
    Dermatol Online J; 2018 Jul; 24(7):. PubMed ID: 30261565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter case series documenting Medicare Part D plan denials of immunosuppressant drug coverage for organ transplant recipients.
    Lushin EN; McDermott JK; Truax C; Lourenco LM; Mariski M; Melaragno JI; Potter LM
    Am J Transplant; 2021 Feb; 21(2):889-896. PubMed ID: 32976706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concordance of severity ratings provided in four drug interaction compendia.
    Abarca J; Malone DC; Armstrong EP; Grizzle AJ; Hansten PD; Van Bergen RC; Lipton RB
    J Am Pharm Assoc (2003); 2004; 44(2):136-41. PubMed ID: 15098847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of potentially hepatotoxic drugs among major US drug compendia.
    Guo JJ; Wigle PR; Lammers K; Vu O
    Res Social Adm Pharm; 2005 Sep; 1(3):460-79. PubMed ID: 17138490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Off-label prescribing in the treatment of dermatologic disease.
    Sugarman JH; Fleischer AB; Feldman SR
    J Am Acad Dermatol; 2002 Aug; 47(2):217-23. PubMed ID: 12140467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Off-label uses of biologic agents in dermatology: a 2006 update.
    Kerns MJ; Graves JE; Smith DI; Heffernan MP
    Semin Cutan Med Surg; 2006 Dec; 25(4):226-40. PubMed ID: 17174843
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.